Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress

Status Completed

Clinical Trial Summary

In comparison to the general population, military personnel and veterans are at increased risk of developing both substance use disorders (SUDs) and post-traumatic stress disorder (PTSD). Despite promising developments in the past decade, the treatment of patients with SUDs and comorbid PTSD is woefully inadequate (Back, 2010; Back et al., 2014; Brady et al., 2007; McCauley et al., 2012). One of the adverse effects of abused drugs is their long-term negative impact on social behavior that is thought to involve oxytocin (OT) dysregulation (McGregor et al., 2008). In preclinical and clinical experiments, local, intra-nasal, or systemic OT administration decreases activation of the amygdala in response to visual fearful/threatening stimuli (Kirsch et al., 2005), ameliorates the effects of stressful events, and decreases drug-taking and seeking behavior (McGregor et al., 2008; Baskerville and Douglas, 2010; Carson et al., 2010a; Bowen et al., 2011; Cox et al 2013). However, little attention has been focused on whether OT decreases SUD vulnerability after exposure to traumatic stress in preclinical or clinical studies. This clinical project will determine whether intra-nasally administered OT will decrease craving (Aim 1) to use alcohol and decrease stress reactivity (Aim 2) following exposure to laboratory-induced stress (Trier Social Stress Task) among veterans with a dual diagnosis of alcohol use disorder and PTSD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02058251
Study type	Interventional
Source	Medical University of South Carolina
Contact
Status	Completed
Phase	Phase 1
Start date	February 2014
Completion date	April 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02179749` - Mifepristone Treatment of Alcohol Use Disorder	Phase 2
Completed	`NCT02113618` - Effect of Cognitive Training on Alcohol Use Outcomes	N/A
Completed	`NCT01008280` - Baclofen to Reduce Alcohol Use in Veterans With HCV	Phase 4
Active, not recruiting	`NCT02671019` - Effectiveness and Costs of Internet-based Treatment for Harmful Alcohol Use and Face-to-face Treatment in Addiction Care	N/A
Completed	`NCT01751035` - Integrative Risk Reduction and Treatment for Teen Substance Use Problems and PTSD	N/A
Active, not recruiting	`NCT03695653` - Messaging Interventions to Reduce Alcohol Problems Project	N/A
Completed	`NCT02298751` - Exposure Therapy as Aftercare for Alcohol Use Disorder	N/A
Completed	`NCT01642381` - Component Analysis for Motivational Interviewing	N/A
Terminated	`NCT01566370` - Zonisamide for Heavy Drinkers With Bipolar Disorder	Phase 2
Completed	`NCT02511808` - Adaptive Interventions for Problem Drinkers	N/A
Completed	`NCT02384278` - Internet Based Cognitive Behavior Treatment for Alcohol Problems	N/A
Completed	`NCT01613014` - ABT-436 for Alcohol Dependence	Phase 2
Completed	`NCT02905162` - Understanding Longitudinal Clinical Outcomes and Post-release Retention in Care Among HIV-infected Prisoners in Lusaka, Zambia
Completed	`NCT02808468` - Brief Restructuring Intervention Following Trauma Exposure	N/A
Completed	`NCT01692054` - Risk and Protective Factors of Children and Adolescents Who Were Hospitalized Due to Alcohol Intoxication	N/A
Completed	`NCT02500602` - CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders	Phase 2
Active, not recruiting	`NCT02713217` - Implementing a Blended Care Model That Integrates Mental Healthcare and Primary Care Using Telemedicine and Care Management for Patients With Depression or Alcohol Use Disorder in Small Primary Care Clinics
Recruiting	`NCT02465177` - Tailoring Screening, Brief Intervention, and Referral to Treatment for Medical ICU Survivors
Completed	`NCT02193256` - Varenicline + Prazosin for Heavy Drinking Smokers	Early Phase 1
Completed	`NCT01172210` - Examining Common Substrates of Eating and Alcohol Use Disorders	N/A